BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/17/2020 9:42:32 AM | Browse: 877 | Download: 2095
 |
Received |
|
2020-06-18 08:46 |
|
Peer-Review Started |
|
2020-06-18 08:46 |
|
First Decision by Editorial Office Director |
|
2020-09-18 16:58 |
|
Return for Revision |
|
2020-09-18 16:58 |
|
Revised |
|
2020-10-15 06:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-05 10:06 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-05 19:25 |
|
Articles in Press |
|
2020-11-05 19:25 |
|
Edit the Manuscript by Language Editor |
|
2020-11-27 08:38 |
|
Typeset the Manuscript |
|
2020-12-14 09:54 |
|
Publish the Manuscript Online |
|
2020-12-17 09:42 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rahul Trimukhe, Preeti Vani, Arvind Patel and Vikas Salgotra |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Vikas Salgotra, MPhil, Senior Researcher, SLTL Medical Division, SLTL (Sahajanand Laser Technology Ltd.), E30, Electronics Estate, GIDC, Sector 26, Gandhinagar 382016, Gujarat, India. clinical@sltl.com |
| Key Words |
Coronary artery disease; Everolimus; Major adverse cardiac event; Retrospective; EverProTM; Myocardial infarction |
| Core Tip |
New-generation drug-eluting stents (DES) reduce risk of stent thrombosisbut everolimus-eluting coronary stent system (EES) exerts higher interaction with rapamycin complex 2, higher bioavailability, shorter half-life than sirolimus, decreases vascular inflammation and promotes rapid endothelialization; therefore, outperformed paclitaxel DES in safety and efficacy. EverProTM, a second-generation EES with biodegradable polymer and a 60 μm cobalt-chromium platform design, facilitates reduction of intra-arterial injury. This observational study enrolled 77 patients with coronary artery disease (CAD), implanted with EverProTM stent having completed 1-years’ follow-up from index procedure. Our findings suggested that EverProTM EES is safe and effective with no major adverse cardiac events/stent thrombosis up to 1 year in patients with CAD. |
| Publish Date |
2020-12-17 09:42 |
| Citation |
Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020; 12(12): 615-625 |
| URL |
https://www.wjgnet.com/1949-8462/full/v12/i12/615.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v12.i12.615 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
